Managing asthma often requires a two-pronged approach — long-term medicines to prevent attacks and rescue strategies to stop attacks when they happen. It’s important to avoid triggers and monitor ...
Early Phase I data showed inhaled londamocitinib reduced airway inflammation in mild asthma with good tolerability. Learn ...
A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...
Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more comfortably. But researchers at Karolinska Institutet have uncovered a surprising ...
Apogee Therapeutics, Inc. (NASDAQ: APGE) on Tuesday shared interim data from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma. The data covers 19 adult patients ...
What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...
Bulletin: ...WINTER WEATHER ADVISORY IN EFFECT FROM 4 AM TO 10 AM EST TUESDAY... * WHAT...Snow expected. Total snow and sleet accumulations between 1 and 3 inches ...
Hosted on MSN
Life-saving asthma drug taken twice a year slashes hospital admissions by three-quarters
A twice-yearly injection that could prevent thousands of asthma patients from suffering life-threatening attacks will go on sale in Britain within months. Trials show the ‘ultra-long-acting’ drug, ...
Asthma is one of the most prevalent chronic inflammatory respiratory diseases across the globe, with a significant increase ...
An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available in Britain. The pharmaceutical giant GSK has been granted marketing ...
The policy shift has prompted safety concerns from doctors and patient advocates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results